PHARMA POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ

TAX ID9571063760

KRS0000408855

Share capital250,000.00 zł

★ ★ ★ ★ ★ ★ ★ ★ ★ ★

No opinion. Add your first review

address

GDYNIA, GDYNIA

Show on map

Is this your company?Update company information to get new customers, get notified of new reviews, and more!

Register Data

Full name

PHARMA POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ

uses securityreCAPTCHA

Privacy – Terms of Use

Legal address

GDYNIA, GDYNIA

Show on map

NIP

9571063760

REGON

221600743

KRS

0000408855

Legal form

limited liability company

Register Address

GDYNIA, GDYNIA

Date of registration in KRS

2012-01-20

Date of commencement of economic activity

2012-01-20

Act signature

GD.VIII NS-REJ.KRS/22398/24/570

Pkd codes

46.75.Z - Wholesale trade

46 - Wholesale trade

47 - Retail trade

70 - Head office activities and management consultancy

72 - Scientific research and development activities

73 - Advertising, market research and public relations

82 - Office administrative support activities and other business support services

Payer VAT status

Unregirestered

Company authorities

representation authorityMANAGEMENT

representation type

DO SKŁADANIA OŚWIADCZEŃ I PODPISYWANIA W IMIENIU SPÓŁKI UPRAWNIONY JEST KAŻDY Z CZŁONKÓW ZARZĄDU SAMODZIELNIE.

shareholders

STREAMBRIDGE LIMITED

100% 2500 udziałów o łącznej wartości 250.000,00 złotych

Financial data

Net sales [PLN]

Gross profit / loss [PLN]

Automatically generated based on financial statements from KRS Registry

	2020	2021	2022
	M PLN	M PLN	M PLN	%
Gross profit (loss)	1,4	0,4	-2,9	-896,6
EBITDA	1,7	0,5	-3	-751,5
Short time liabilities	6,2	4,8	0,5	-88,8
Equity capital	2,5	2,6	-0,3	-111,5
Operating profit (EBIT)	1,5	0,3	-3,1	-1250,3
Assets	8,8	7,5	0,2	-96,8
Net profit (loss)	1,2	0,1	-2,9	-3193
Cash	1,2	0,1	0	-98,9
Net income from sale	83,4	71,2	4,6	-93,5
Liabilities and provisions for liabilities	6,3	4,9	0,5	-88,9
Working assets	8,3	7,1	0,1	-98,1
Depreciation	0,2	0,2	0,2	-5,8
	%	%	%	p.p.
Profitability of capital	48,5	3,6	969,9	966,3
Equity capital to total assets	28,5	34,9	-124,4	-159,3
Gross profit margin	1,7	0,5	-62,6	-63,1
EBITDA Margin	2	0,6	-64	-64,6
	Days	Days	Days	Days
Short term commitment turnover cycle	27	25	42	17